CHARGED ALPHATMFrontier AI stock research

RPRX · NasdaqGS

Royalty Pharma plc

Biotechnology · United States

USD 68.680.2% daily changeQuote 2026-11-17 · USD
Market cap (USD)
US$39.49B
Trailing P/E
44.89x
Forward P/E
11.62x
Quarterly revenue growth
13.3%
Trailing net margin
25.7%
Indicated dividend yield
1.4%

Snapshot 2026-11-18 · Latest financial period 2026-09-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.

Company background

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Company website

Q2 2026

Go beyond the headline.

Royalty Pharma (RPRX) Q2 2026 Earnings: The Biggest Royalty It Owns Grew Zero Percent

Published 2026-08-08

Comparable businesses

RPRX peer comparison

Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.

Comparison stocks

No suitable peers with fresh, comparable size data are available. We have not substituted unrelated companies.

Market metrics · missing or inapplicable values shown as —
MetricRPRXRoyalty Pharma plcSnapshot 2026-11-18Financial period: 2026-09-30
Market capMarket value, converted to USDUS$39.49B
Forward P/EProvider forward earnings estimate11.62x
EV / EBITDAEnterprise value / trailing EBITDA24.59x
Revenue growthLatest quarter vs prior-year quarter13.3%
Operating marginLatest reported quarter64.4%
Free cash flow yieldTrailing cash flow / market cap-1.1%
Net debt / EBITDANet debt / trailing EBITDA4.76x
Debt / equityTotal debt / positive book equity0.88x
Trailing P/ETrailing twelve-month earnings44.89x
Price / bookPrice / positive book equity per share4.48x
EV / salesEnterprise value / trailing revenue15.89x
Earnings growthLatest quarter vs prior-year quarter-50.8%
Gross marginTrailing twelve months99.8%
Net marginTrailing twelve months25.7%
Return on equityProvider trailing return; positive equity only12.1%
Free cash flow marginTrailing free cash flow / revenue-17.2%
Dividend yieldIndicated annual dividend / price1.4%
Earnings payoutProvider trailing dividend payout60.5%
Current ratioCurrent assets / current liabilities1.29x
BetaProvider historical market sensitivity0.36

Choose a comparison stock

Search covered companies, or search all listed stocks.

Comparison methodology & limitations

Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.

Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.

Reported performance

Financial trends

Reporting period
Financial history
Chart style
Comparison stocks

Financial statements load separately from the research page.

Market context

Valuation & price history

Adjusted closing price

Price history

Price history loads separately.

Earnings-multiple scenario

Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.

Starting assumptions, when available, use provider forward estimates as of 2026-11-18. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.

THE RESEARCH RECORD

Research history for RPRX

All available reporting periods
Q2 20262026-08-08

Reported figures

Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.